Figure 1. Antibiotic approvals over the last three decades in five-year increments. In 1983-1987 the FDA approved 16 new systemic antibiotics, but since that time antibiotic approvals have been on the decline. Since 2008, only two systemic antibiotics have been approved. Vibativ telavancin from Theravance Inc. was approved in 2009 to treat acute bacterial skin and skin structure infections (ABSSSI), and Teflaro ceftaroline from Forest Laboratories Inc. was approved in 2010 to treat community-acquired bacterial pneumonia (CABP) and ABSSSI. (Figure based on Figure 1 in ref. 1.)

Source: Spellberg et al.; BCIQ: BioCentury Online Intelligence